Citations

Showing 10 of 108104 citations.

Reconstruction of a Defect on the Dorsal Third Digit
Criscito, Maressa C., Lachman, Nirusha, Carucci, John A., Criscito, Maressa C., Lachman, Nirusha, Carucci, John A.

Mayo Clinic

Dermatologic Surgery | January 23, 2022 | Volume: 48 | Issue: 12 | Pages: 1351-1353

10.1097/dss.0000000000003364 | PMID 35066547 Get It

Device‐related infection associated with increased mortality risk in de novo transvenous implantable cardioverter‐defibrillator medicare patients
Liu, Yiyan , Griffiths, Robert I. , Knight, Bradley P. , Weiss, Raul , Mark, George E., Lambiase, Pier D. , Miller, Marc A. , Jacobsen, Caroline M., El-Chami, Mikhael F , Weiss, Raul , Miller, Marc A , Lambiase, Pier D , Knight, Bradley P , El‐Chami, Mikhael F. , Biffi, Mauro , Probst, Vincent , Baddour, Larry M.

Mayo Clinic

Journal of Cardiovascular Electrophysiology | January 23, 2022 | Volume: 33 | Issue: 4 | Pages: 725-730

10.1111/jce.15385 | PMID 35066954 Get It

AbstractIntroductionTransvenous implantable cardioverter‐defibrillators (TV‐ICD) infection is a serious complication that frequently requires complete device removal for attempted cure, which can be associated with patient morbidity and mortality. The objective of this study is to assess mortality risk associated with TV‐ICD infection in a large Medicare population with de novo TV‐ICD implants.MethodsA survival analysis was conducted using 100% fee‐for‐service Medicare facility‐level claims data to identify patients who underwent de novo TV‐ICD implantation between 7/2016 and 1/2018. TV‐ICD infection within 2 years of implantation was identified using International Classification of Disease, 10th Edition and current procedural terminology codes. Baseline patient risk factors associated with mortality were identified using the Charlson Comorbidity Index categories. Infection was treated as a time‐dependent variable in a multivariate Cox proportional hazards model to account for immortal time bias.ResultsAmong 26,742 Medicare patients with de novo TV‐ICD, 518 (1.9%) had a device‐related infection. The overall number of decedents was 4721 (17.7%) over 2 years, with 4555 (17%) in the noninfection group and 166 (32%) in the infection group. After adjusting for baseline patient demographic characteristics and various comorbidities, the presence of TV‐ICD infection was associated with an increase of 2.4 (95% CI: 2.08–2.85) times in the mortality hazard ratio.ConclusionThe rate of TV‐ICD infection and associated mortality in a large, real‐world Medicare population is noteworthy. The positive association between device‐related infection and risk of mortality further highlights the need to reduce infections
Safety of magnetic resonance imaging in patients with cardiac implantable electronic devices with generator and lead(s) brand mismatch
Minaskeian, Nareg , Hajnal, Sofia Pannunzio, Liu, Michael B. , Klooster, Lindsay, Devick, Katrina L. , Schwartz, Linda, Jokerst, Clinton, Sorajja, Dan , Scott, Luis, Hajnal, Sofia P, Klooster, Lindsay M, Scott, Luis Rp, Schwartz, Linda

Mayo Clinic

Journal of Applied Clinical Medical Physics | January 23, 2022 | Volume: 23 | Issue: 3 | Pages: No page available

10.1002/acm2.13520 | PMID 35066975 Get It

AbstractMagnetic resonance imaging (MRI) is a valuable imaging modality for the assessment of both cardiac and non‐cardiac structures. With a growing population of patients with cardiovascular implantable electronic devices (CIEDs), 50%–75% of these patients will need an MRI. MRI‐conditional CIEDs have demonstrated safety of MRI scanning with such devices, yet non‐conditional devices such as hybrid CIEDs which have generator and lead brand mismatch may pose a safety risk. In this retrospective study, we examined the outcomes of patients with hybrid CIEDs undergoing MRI compared to those patients with non‐hybrid CIEDs. A total of 349 patients were included, of which 24 patients (7%) had hybrid CIEDs. The primary endpoint was the safety of MRI for patients with hybrid CIEDs as compared to those with non‐hybrid devices, measured by the rate of adverse events, including death, lead or generator failure needing immediate replacement, loss of capture, new onset arrhythmia, or power‐on reset. Secondary endpoints consisted of pre‐ and post‐MRI changes of decreased P‐wave or R‐wave sensing by ≥50%, changes in pacing lead impedance by ≥50 ohms, increase in pacing thresholds by ≥ 0.5 V at 0.4 ms, and decreasing battery voltage of ≥ 0.04 V. The primary endpoint of any adverse reaction was present in 1 (4.2%) patient with a hybrid device, and consistent of atrial tachyarrhythmia, and in 10 (3.1%) patients with a non‐hybrid device, and consisted of self‐limited atrial and non‐sustained ventricular arrhythmias; this was not statistically significant. No significant differences were found in the secondary endpoints. This study demonstrates that MRI in patients with hybrid CIEDs does not result in increased patient risk or significant device changes when compared to those patients who underwent MRI with non‐hybrid CIEDs.
AAPM Task Group Report 290: Respiratory motion management for particle therapy
Li, Heng , Flampouri, Stella , Jee, Kyung‐Wook , Lin, Liyong , Moyers, Michael F. , Rottmann, J, Tryggestad, E., Vedam, Sastry, Tryggestad, Erik, Lin, Liyong , Dong, Lei , Bert, Christoph , Chang, Joe Y. , Mori, Shinichiro

Mayo Clinic

Medical Physics | January 23, 2022 | Volume: 49 | Issue: 4 | Pages: No page available

10.1002/mp.15470 | PMID 35066871 Get It

Abstract Dose uncertainty induced by respiratory motion remains a major concern for treating thoracic and abdominal lesions using particle beams. This Task Group report reviews the impact of tumor motion and dosimetric considerations in particle radiotherapy, current motion‐management techniques, and limitations for different particle‐beam delivery modes (i.e., passive scattering, uniform scanning, and pencil‐beam scanning). Furthermore, the report provides guidance and risk analysis for quality assurance of the motion‐management procedures to ensure consistency and accuracy, and discusses future development and emerging motion‐management strategies. This report supplements previously published AAPM report TG76, and considers aspects of motion management that are crucial to the accurate and safe delivery of particle‐beam therapy. To that end, this report produces general recommendations for commissioning and facility‐specific dosimetric characterization, motion assessment, treatment planning, active and passive motion‐management techniques, image guidance and related decision‐making, monitoring throughout therapy, and recommendations for vendors. Key among these recommendations are that: (1) facilities should perform thorough planning studies (using retrospective data) and develop standard operating procedures that address all aspects of therapy for any treatment site involving respiratory motion; (2) a risk‐based methodology should be adopted for quality management and ongoing process improvement.
Association of serum potassium derangements with mortality among patients requiring continuous renal replacement therapy
Thongprayoon, Charat , Cheungpasitporn, Wisit , Radhakrishnan, Yeshwanter , Genovez, Jose L. Zabala , Shawwa, Khaled , Zabala Genovez, Jose L, Cheungpasitporn, Wisit , Thongprayoon, Charat , Radhakrishnan, Yeshwanter , Petnak, Tananchai , Qureshi, Fawad , Mao, Michael A. , Kashani, Kianoush

Mayo Clinic

Therapeutic Apheresis and Dialysis | January 23, 2022 | Volume: 26 | Issue: 6 | Pages: 1098-1105

10.1111/1744-9987.13804 | PMID 35067000 Get It

AbstractIntroductionWe aimed to assess the association between serum potassium and mortality in patients receiving continuous renal replacement therapy (CRRT).MethodsWe studied 1279 acute kidney injury patients receiving CRRT in a tertiary referral hospital in the United States. We used logistic regression to assess the association of serum potassium before CRRT and mean serum potassium during CRRT with 90‐day mortality after CRRT initiation, using serum potassium 4.0–4.4 mmol/L as reference group.ResultsBefore CRRT, there was a U‐shaped association between serum potassium and 90‐day mortality. There was a significant increase in mortality when serum potassium before CRRT was ≤3.4 and ≥4.5 mmol/L. During CRRT, progressively increased mortality was noted when mean serum potassium was ≥4.5 mmol/L. The odds ratio of 90‐day mortality was significantly higher when mean serum potassium was ≥4.5 mmol/L.ConclusionHypokalemia and hyperkalemia before CRRT and hyperkalemia during CRRT predicts 90‐day mortality.
Exploring the Validity Based on Internal Structure of the Oldenburg Burnout Inventory – Medical Student (OLBI-MS)
Runyon, Christopher , Runyon, Christopher R , Dyrbye, Liselotte N. , Paniagua, Miguel

Mayo Clinic

Teaching and Learning in Medicine | January 22, 2022 | Volume: 35 | Issue: 1 | Pages: 37-51

10.1080/10401334.2021.2018695 | PMID 35068287 Get It

Incidence and prevalence of immune‐mediated necrotizing myopathy in adults in Olmsted County, Minnesota
Shelly, Shahar , Paul, Pritikanta , Milone, Margherita , Tracy, Jennifer A., Mills, John R. , Ernste, Floranne C. , Mandrekar, Jay , Liewluck, Teerin , Paul, Pritikanta , Liewluck, T , Shahar, Shelly , Mielke, Michelle M. , Klein, Christopher J.

Mayo Clinic

Muscle & Nerve | January 22, 2022 | Volume: 65 | Issue: 5 | Pages: 541-546

10.1002/mus.27504 | PMID 35064938 Get It

AbstractIntroduction/AimsImmune‐mediated necrotizing myopathy (IMNM) is considered a rare subtype of the immune‐mediated myopathies, but its incidence and prevalence are unknown. In this study we aimed to determine the incidence and prevalence of IMNM among adults in Olmsted County, Minnesota.MethodsWe identified adult patients with IMNM, as defined by the 2016 European Neuromuscular Centre diagnostic criteria, among residents of Olmsted County, Minnesota over a 20‐year period.ResultsSeven patients fulfilled the inclusion criteria. Six patients were tested for IMNM antibodies: four were anti–3‐hydroxy‐3‐methylglutaryl‐coenzyme A reductase (HMGCR) positive, one was anti–signal recognition particle positive, and one was seronegative. The incidence of IMNM during 2010‐2019 was 8.3 per million person‐years. The prevalence of IMNM in 2010 was 1.85 per 100 000 people at least 50 years of age. Median age at symptom onset was 64 (range, 52‐86) years and median time from symptom onset to diagnosis was 3 (range, <1 to 156) months. Statin use among anti‐HMGCR IMNM patients, but not the entire IMNM cohort, was higher than in controls (P = .024). Two IMNM patients developed cancers. The incidence of malignancy in IMNM was not higher than that of the general population. Treatment outcome was favorable in all patients except for one patient with delayed treatment and another with insufficient therapy. Among three deceased patients, one died of cancer and another died of IMNM‐related cardiorespiratory complications.DiscussionIMNM is a rare disease. Its prevalence is one tenth that of inclusion‐body myositis in Olmsted County, Minnesota. IMNM patients in our cohort were not at higher risk for developing cancer.
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Tri
Castro, Januario E. , Lengerke-Diaz, Paula A. , Luján, Juliana Vélez, Choi, Michael Y. , Moreno-Cortes, Eider , Forero-Forero, José Vicente , García-Robledo, Juan Esteban , Jacobs, C , McCarthy, Colin, Heinen, Alaina, Amaya-Chanaga, Carlos I., Moreno-Cortes, Eider F , Forero, Jose V , Jacobs, Chaja , Kipps, Thomas J , Castro, Januario E , Garcia-Robledo, Juan Esteban , Diaz, Paula A Lengerke , Kipps, Thomas J.

Mayo Clinic

Advances in Hematology | January 22, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-8

10.1155/2022/4450824 | PMID 35103064 Get It

Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation. We enrolled 32 therapy-naïve CLL patients to receive ibrutinib plus obinutuzumab, followed by single-agent ibrutinib. Patients could discontinue ibrutinib after 36 months with sustained complete response (CR). We evaluated treatment safety, efficacy, and outcomes after ibrutinib discontinuation. The overall response rate was 100%, 28% achieved a CR, and 12.5% achieved bone marrow undetectable minimal residual disease. At a three-year median follow-up, 91% remain in remission with 100% overall survival. Five patients in sustained CR stopped ibrutinib and have not progressed. Eight non-CR patients discontinued for other reasons, with only two progressing. The treatment was safe, with a lower IRR rate. All patients responded to treatment with longer time-to-progression after discontinuation of ibrutinib. Our data support the evaluation of ibrutinib discontinuation strategies in more extensive clinical trials (https://Clinicaltrials.gov Identifier https://clinicaltrials.gov/ct2/show/NCT02315768).
Characterization and commissioning of a Leksell Gamma Knife ICON system for framed and frameless stereotactic radiosurgery
Hu, Yue‐Houng , Hickling, Susannah , Qian, J. , Blackwell, C. Robert, McLemore, Luke B., Tryggestad, E., Hickling, Susannah V, Qian, Jing , Tryggestad, Erik J, Qian, Jing

Mayo Clinic

Journal of Applied Clinical Medical Physics | January 22, 2022 | Volume: 23 | Issue: 3 | Pages: No page available

10.1002/acm2.13475 | PMID 35064749 Get It

AbstractPurposeThe Leksell Gamma Knife Icon unit (IU) was introduced recently as an upgrade to the Perfexion unit (PU) at our Gamma Knife practice. In the current study, we sought mainly to characterize dosimetry and targeting accuracy of the IU treatment deliveries using both invasive frame and frameless treatment workflows.MethodsRelative output factors were measured by delivering single‐shot 4, 8 and 16 mm radiation profiles in the manufacturer's acrylonitrile butadiene styrene spherical phantom in coronal and sagittal planes using EBT3 film. Resultant dosimetry was compared with the manufacturer's dose calculation and derived output factors were compared with the manufacturer's published value. Geometric consistency of stereotactic coordinates based on cone‐beam computed tomography (CBCT) versus the traditional conventional CT‐based method was characterized using a rigid phantom containing nine fiducial indicators over four separate trials. End‐to‐end (E2E) testing using EBT3 film was designed to evaluate both dosimetric and geometric accuracy for hypothetical framed and frameless workflows.ResultsRelative output factors as measured by the manufacturer were independently confirmed using EBT3 film measurements to within 2%. The mean 3D radial discrepancy in stereotactic space between CBCT and CT‐based definition over the sampled locations in our rigid geometry phantom was demonstrated to be between 0.40 mm and 0.56 mm over the set of trials, larger than prior reported values. E2E performed in 2D demonstrates sub‐mm (and typically < 0.5 mm) accuracy for framed and frameless workflows; geometric accuracy of framed treatments using CBCT‐defined stereotactic coordinates was shown to be slightly improved in comparison with those defined using conventional CT. Furthermore, in phantom, frameless workflows exhibited better accuracy than framed workflows for fractionated treatments, despite large magnitudes of introduced interfraction setup error. Accuracy of dosimetric delivery was confirmed in terms of qualitative comparisons of dose profiles and in terms of 2D gamma pass rates based on 1%/1 mm criteria.ConclusionThe IU was commissioned for clinical use of frameless and framed treatment protocols. The present study outlines an extensive E2E methodology for confirmation of dosimetric and geometric treatment accuracy.
Pemphigoid gestationis and polymorphic eruption of pregnancy in skin of color
Xie, Fangyi , Sominidi‐Damodaran, Sindhuja , Wyles, Saranya P. , Wieland, Carilyn N. , Comfere, Nneka I. , Lehman, Julia S. , Cantwell, Hafsa M. , Lehman, Julia S , Davis, Dawn Marie R.

Mayo Clinic

International Journal of Dermatology | January 22, 2022 | Volume: 62 | Issue: 2 | Pages: No page available

10.1111/ijd.16048 | PMID 35064677 Get It